Aravax Company

Aravax is an early stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy. The company is using their proprietary technology to reset the immune system to tolerate peanut without evoking allergic reactions during treatment. Aravax was founded in May 2015 through acquisition of intellectual property developed by Alfred Health and Monash University. Aravax has its headquarters in Melbourne, Australia.
Technology: Personalised Medicine
Industry: P4 Medicine
Headquarters: Others
Founded Date: 2015-01-01
Funding Status: Seed
Investors Number: 2
Last Funding Type: Seed

Visit Website
Register and Claim Ownership